logo
Share SHARE
FONT-SIZE Plus   Neg

Pernix Subsidiaries Receives Approval For VITUZ, Mefenamic Acid Capsules

Hawthorn Pharmaceuticals, Inc., a subsidiary of Pernix Therapeutics Holdings, Inc. (PTX) Thursday said it has received approval from the U.S. Food and Drug Administration, or FDA, for VITUZ Oral Solution.

VITUZ solution is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older.

The company also said that its subsidiary, Cypress Pharmaceuticals, Inc., has been granted final approval by the FDA for Mefenamic Acid Capsules USP, 250 mg, a generic version of Ponstel Capsules, 250 mg, indicated for relief of mild-to-moderate pain in patients treated of primary dysmenorrhea.

"VITUZ broadens our cough and cold product line and is our first NDA approved by the FDA, since the acquisition of Hawthorn and Cypress, " said Cooper Collins, President, CEO.

Launch of the new treatment option for cough and cold symptoms is expected prior to the fall of 2012. Mefenamic Acid Capsules are expected to launch in the second quarter.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Spanish fashion retailer Industria de Diseño Textil SA or Inditex reported Wednesday higher profit in its first half with strong like-for-like sales growth growth. EBITDA, a key earnings metric, improved 9 percent, while gross margin declined. Inditex shares were losing around 3 percent in the morning trading. Microsoft (MSFT) announced Wednesday that Xbox One X standard edition is now available to pre-order worldwide. The company said more than 130 games have now been enhanced for the system. Beginning today, the console, said to be the most powerful ever, can be booked from local retailers around the... German industrial conglomerate thyssenKrupp AG announced Wednesday that it has signed a memorandum of understanding or MoU with Tata Steel Ltd. about the combination of their European steel activities in a 50/50 joint venture. The companies expect up to 4000 job cuts in the joint venture.
comments powered by Disqus
Follow RTT